Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade

Parkinsonism and Related Disorders

Volumn 2, Issue 4, 1996, Pages 167-175

  Stoessl, A Jon ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antisense; Basal ganglia; Dopamine receptors; Knockout; Parkinson's disease

Indexed keywords

EID: 0042231896     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(96)00022-3     Document Type: Review

References (124)

1. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 93-96.
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483.
3. Calne DB, Teychenne PF, Claveria LE, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. Br. Med. J. 1974; 4: 442-444.
4. Calne DB. Dopamine receptor in movement disorders. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths; 1982: 348-355.
5. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990; 40: 927-933.
6. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J. Pharmacol. Exp. Ther. 1993; 267: 275-279.
7. Taylor JR, Lawrence MS, Redmond Jr DE, Elsworth JD, Roth RH, Nichols DE, Mailman RB. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. 1991; 199: 389-391.
8. Molloy AG, Waddington JL. Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SKF 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology 1987; 92: 164-168.
9. Rosengarten H, Schweitzer JW, Friedhoff AJ. Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci. 1983; 33: 2479-2482.
10. Murray AM, Waddington JL. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur. J. Pharmacol. 1989; 160: 377-384.
11. Rosengarten H, Schweitzer JW, Friedhoff AJ. Selective dopamine D2 receptor reduction enhances a D1 mediated oral dyskinesia in rats. Life Sci. 1986; 39: 29-35.
12. Setler PE, Sarau HM, Zirkle CL, Saunders HL. The central effects of a novel dopamine agonist. Eur. J. Pharmacol. 1978; 50: 419-430.
13. Arnt J. Hyperactivity induced by stimulation of separate D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions. Life Sci. 1985; 37: 717-723.
14. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J. Neural Transmiss. 1987; 68: 41-50.
15. Tsui JKC, Wolters ECh, Peppard RF, Calne DB. A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease. Neurology 1989; 39: 856-858.
16. Pugh MT, O'Boyle KM, Molloy AG, Waddington JL. Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU 24213. Psychopharmacology 1985; 87: 308-312.
17. Braun AR, Chase TN. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur. J. Pharmacol. 1986; 131: 301-306.
18. Jackson DM, Hashizume M. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF 38393. Psychopharmacology 1986; 90: 147-149.
19. Robertson GS, Robertson HA. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res. 1986; 384: 387-390.
20. Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 1987; 236: 719-7222.
21. White FJ, Bednarz LM, Wachtel SR, Hjorth S, Broderson RJ. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?. Pharmacol. Biochem. Behav. 1988; 30: 189-193.
22. Hu X-T, Wachtel SR, Galloway MP, White FJ. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J. Neuroscience 1990; 10: 2318-2329.
23. Seeman P, Niznik HB, Guan H-C, Booth G, Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc. Natl. Acad. Sci. USA 1989; 86: 10156-10160.
24. Stoessl AJ, Dourish CT, Iversen SD. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective D1 and D2 receptor antagonists. Psychopharmacology 1989; 98: 372-379.
25. Caine SB, Heinrichs SC, Coffin VL, Koob GF. Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res. 1995; 692: 47-56.
26. Shippenberg TS, Heidbreder C. Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J. Pharmacol. Exp. Ther. 1995; 273: 808-815.
27. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA. SCH 23390, a potential benzazepine antipsychotic with unique inter-actions on dopaminergic systems. J. Pharmacol. Exp. Ther. 1983; 226: 462-468.
28. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1-dopamine and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Archs Gen. Psychiat. 1992; 49: 538-544.
29. Daly SA, Waddington JL. The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist RU 24213. Br. J. Pharmacol. 1994; 113: 839-844.
30. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptor in prefrontal cortex: involvement in working memory. Science 1991; 251: 947-950.
31. Bunzow JR, van Tol HHM, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988; 336: 783-787.
32. Giros B, Sokoloff P, Martres M-P, Riou J-F, Emorine LJ, Schwartz J-C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989; 342: 923-929.
33. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, Gelernter JE, Rozmahel R, Yang Y, Israel Y, Seeman P, O'Dowd BF. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990; 347:80-83.
34. Zhou Q-Y, Grandy DK, Thambi L, Kushner JA, Van Tol HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O. Cloning and expression of human and rat D1 dopamine receptors. Nature 1990; 347: 76-80.
35. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-150.
36. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614.
37. Sunahara RK, Guan H-C, O'Dowd BF, Seeman P, Laurier LG, Ng C, George SR, Torchia J, Van Tol HHM, Niznik HB. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350: 614-619.
38. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. TIPS 1994; 15: 264-270.
39. Sokoloff P, Schwartz J-C. Novel dopamine receptors half a decade later. TIPS 1995; 16: 270-275.
40. Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991; 564: 203-219.
41. Herroelen L, Debacker JP, Wilczak N, Flamez A, Vauquelin G, DeKeyser J. Autoradiographic distribution of D-3-type dopamine receptors in human brain using [H-3]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res. 1994; 648: 222-228.
42. Svensson K, Carlsson A, Waters N. Locomotor inhibition by the D-3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J. Neural Transmiss. 1994; 95: 71-74.
43. Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993; 260: 1814-1816.
44. Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-445.
45. Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neuroscience 1995; 15: 2186-2191.
46. Matsumoto M, Hikada K, Tada S, Tasaki Y, Yamaguchi T. Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J. Neurochem. 1996; 66: 915-919.
47. Choi WS, Machida CA, Ronnekleiv OK. Distribution of dopamine D1, D2 and D5 receptor mRNAs in the monkey brain: ribonuclease protection assay analysis. Mol. Brain Res. 1995; 31: 86-94.
48. Bergson C, MrzIjak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic P. Regional, cellular, and subcellular variations in the distribution of D-1 and D-5 dopamine receptors in primate brain. J. Neuroscience 1995; 15: 7821-7836.
49. Majzoub JA, Muglia LJ. Knockout mice. N. Engl. J. Med. 1996; 334: 904-907.
50. Forrest D, Yuzaki M, Soares HD, Ng L, Luk DC, Sheng M, Stewart CL, Morgan JI, Connor JA, Curran T. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 1994; 13: 325-338.
51. Drago J, Gerfen CR, Lachowitz JE, Steiner H, Hollon TR, Love PE, Ooi GT, Grinberg A, Lee EJ, Huang SP, Bartlett PF, Jose PA, Sibley DR. Altered striatal function in a mutant mouse lacking D-1A dopamine receptors. Proc. Natl. Acad. Sci. USA 1994; 91: 12564-12568.
52. Lajiness ME, Chio CL, Huff RM. D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylation. J. Pharmacol Exp. Ther. 1993; 267: 1573-1581.
53. Pilon C, Levesque D, Dimitriadou V, Griffon N, et al. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur. J. Pharmacol. 1994; 15: 129-139.
54. Conover JC, Erickson JT, Katz DM, Bianchi LM, Poueymirou WT, McClain J, Pan L, Helgren M, Ip NY, Boland P, Friedman B, Wiegand S, et al. Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. Nature 1995; 375:235-238.
55. Liu X, Ernfors P, Wu H, Jaenisch R. Sensory but not motor neuron deficits in mice lacking NT4 and BDNF. Nature 1995; 375: 238-241.
56. Rosahl TW, Geppert M, Spillane D, Herz J, Hammer RE, Malenka RC, Sudhof TC. Short-term synaptic plasticity is altered in mice lacking synapsin I. Cell 1993; 75: 661-670.
57. Pilowsky PM, Suzuki S, Minson JB. Antisense oligonucleotides: a new tool in neuroscience. Clin. Exp. Pharmacol. Physiol. 1994; 21: 935-944.
58. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 1994; 15: 42-46.
59. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265:1883-1885.
60. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, Torchia M, Burton D, Yang SL, DeArmond SJ. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. USA 1993; 90: 10608-10612.
61. Dutch-Belgian Fragile X Consortium. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994; 78:23-33.
62. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506-1510.
63. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995; 269: 234-238.
64. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269: 230-234.
65. Gunther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, Lang Y, Crestani F, Aguzzi A, Arigoni M, Bluethmann H, Mohler H, Luscher B. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma(2) subunit gene of gamma-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. USA 1995; 92: 7749-7753.
66. Stevens CF, Tonegawa S, Wang Y. The role of calcium-calmodulin kinase II in three forms of synaptic plasticity. Curr. Biol. 1994; 4: 687-693.
67. Abeliovich A, Chen C, Goda Y, Silva AJ, Stevens CF, Tonegawa S. Modified hippocampal long-term potentiation in PKC gamma-mutant mice. Cell 1993; 75:1253-1262.
68. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S. Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mG1uR1 mutant mice. Cell 1994; 79: 365-375.
69. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K, Zwingman TA, Tonegazwa S. Deficient cerebellar long-term depression and impaired motor learning in mG1uR1 mutant mice. Cell 1994; 79: 377-388.
70. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, LeNovere N, Vincent P, Pich EM, Brulet P, Changeux J-P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995; 374: 65-67.
71. Chen C, Rainnie DG, Greene RW, Tonegawa S. Abnormal fear response and aggressive behavior in mutant mice deficient for alpha-calcium-calmodulin kinase II. Science 1994; 266: 291-294.
72. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Muller U, Aguet M, Babinet C, Shih JC, De Maeyer E. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995; 268: 1763-1766.
73. Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, Segu L, Buhot M-C, Hen R. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 1994; 265: 1875-1878.
74. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-546.
75. Condron BG, Patel NH, Zinn K. Engrailed conrols glial/neuronal cell fate decisions at the midline of the central nervous system. Neuron 1994; 13: 541-554.
76. Rothstein JD, Bristol LA, Hosler B, Brown RH Jr, Knucl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc. Natl. Acad. Sci. USA 1994; 91: 4155-4159.
77. Konradi C, Cole RL, Heckers S, Hyman SE. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J. Neuroscience 1994; 14: 5623-5634.
78. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Reis DJ, Inturrisi CE. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 1993; 363: 260-263.
79. Caceres A, Mautino J, Kosik KS. Suppression of MAP2 in cultured cerebellar macroneurons inhibits minor neurite formation. Neuron 1992; 9: 607-618.
80. Ferreira A, Niclas J, Vale RD, Banker G, Kosik KS. Suppression of kinesin expression in cultured hippocampal neurons using antisense oligonucleotides. J. Cell Biol. 1992; 117: 595-606.
81. Caceres A, Kosik KS. Inhibition of neurite polarity by tau anti-sense oligonucleotides in primary cerebellar neurons. Nature 1990; 343: 461-463.
82. Ferreira A, Kosik KS, Greengard P, Han HQ. Aberrant neurites and synaptic vesicle protein deficiency in synapsin II-depleted neurons. Science 1994; 264: 977-979.
83. Allinquant B, Hantraye P, Mailleux P, Moya K, Bouillot C, Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 1995; 128: 919-927.
84. Pizzi M, Valerio A, Ribola M, Spano PF, Memo M. A tau anti-sense oligonucleotide decreases neurone sensitivity to excitotoxic injury. Neuroreport 1993; 4: 823-826.
85. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 1993; 90: 7789-7793.
86. Castro-Alamancos MA, Torres-Aleman I. Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide. Proc. Natl. Acad. Sci. USA 1994; 91: 10203-10207.
87. Neumann I, Porter DW, Landgraf R, Pittman QJ. Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into rat supraoptic nucleus. Am. J. Physiol. 1994; 267: R852-R858.
88. McCarthy MM, Kleopoulos SP, Mobbs CV, Pfaff DW. Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen-induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology 1994; 59: 432-440.
89. Mani SK, Blaustein JD, Allen JM, Law SW, O'Malley BW, Clark JH. Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor. Endocrinology 1994; 135: 1409-1414.
90. McCarthy MM, Masters DB, Rimvall K, Schwartz-Giblin S, Pfaff DW. Intracerebral administration of antisense oligodeoxynucleotides to GAD65 and GAD67 mRNAs modulate reproductive behavior in the female rat. Brain Res. 1994; 636: 209-220.
91. Rossi G, Pan YX, Cheng J, Pasternak GW. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 1994; 54: PL375-PL379.
92. Tseng LF, Collins KA. Antisense oligodeoxynucleotide to a delta-opioid receptor given intrathecally blocks i.c.v. administered beta-endorphin-induced antinociception in the mouse. Life Sci. 1994; 55: PL127-PL131.
93. Sakai RR, He PF, Yang XD, Ma LY, Guo YF, Reilly JJ, Moga CN, Fluharty SJ. Intracerebroventricular administration of ATI receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 1994; 62: 2053-2056.
94. Gyurko R, Wielbo D, Phillips MI. Antisense inhibition of ATI receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 1993; 49: 167-174.
95. Akabayashi A, Wahlestedt C, Alexander JT, Leibowitz SF. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligodeoxynucleotides suppresses feeding behavior and insulin secretion. Mol. Brain Res. 1994; 21: 55-61.
96. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259: 528-531.
97. Skutella T, Criswell H, Moy S, Probst JC, Breese GR, Jirikowski GF, Holsboer F. Corticotropin-releasing hormone (CRH) anti-sense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport 1994; 5: 2181-2185.
98. Chiasson BJ, Hooper ML, Murphy PR, Robertson HA. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmacol. 1992; 227: 451-453.
99. Dragunow M, Lawlor P, Chiasson B, Robertson H. c-fos anti-sense generates apomorphine and amphetamine-induced rotation. Neuroreport 1993; 5: 305-306.
100. Sommer W, Bjelke B, Ganten D, Fuxe K. Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. Neuroreport 1993; 5: 277-280.
101. Merchant KM. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin-N messenger mRNA expression in rat dorsal striatum. Mol. Cell Neurosci. 1994; 5: 336-344.
102. Heilig M, Engel JA, Soderpalm B. c-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. Eur. J. Pharmacol. 1993; 236: 339-340.
103. Tischmeyer W, Grimm R, Schicknick H, Brysch W, Schlingensiepen KH. Sequence-specific impairment of learning by c-jun antisense oligonucleotides. Neuroreport 1994; 5: 1501-1504.
104. Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AM, Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994; 79: 729-742.
105. Xu M, Hu X-T, Cooper DC, Moratalla R, Graybiel AM, White FJ, Tonegawa S. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 1994; 79: 945-955.
106. Baik J-H, Picetti R, Salardi A, Thiriet G, Dierich A, Depaulis A, le Meur M, Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377: 424-428.
107. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432.
108. Bannon MJ, Elliott PJ, Bunney EB. Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. mol. Brain Res. 1987; 3: 31-37.
109. Accili D, Fishburn CS, Drago J, Stiener H, Lachowitz JE, Park B-H, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. USA 1996; 93: 1945-1949.
110. Koeltzow TE, Cooper DC, Hu X-T, Xu M, Tonegawa S, White FJ. In vivo effects of dopaminergic ligands in dopamine D3 receptor deficient mice. Soc. Neurosci. Abstr. 1995; 21: 364.
111. Xu M, Caine SB, Cooper DC, Gold LH, Graybiel AM, Hu XT, Koeltzow T, Koob GF, Moratalla R, White FJ, Tonegawa S. Analyses of dopamine D3 and D1 receptor mutant mice. Soc. Neurosci. Abstr. 1995; 21: 363.
112. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
113. Zhou LW, Zhang SP, Qin ZH, Weiss B. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptor in mouse striatum. J. Pharmacol. Exp. Ther. 1994; 268: 1015-1023.
114. Zhang M, Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci. Lett. 1993; 161: 223-226.
115. Silvia CP, King GR, Lee TH, Xue ZY, Caron MG, Ellinwood EH. Intranigral administration of D2 dopamine receptor anti-sense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Mol. Pharmacol. 1994; 46: 51-57.
116. Rajakumar N, Laurier L, Niznik HB, Stoessl AJ. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviours in the rat Synapse (in press).
117. Stoessl AJ, Dourish CT, Iversen SD. Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. Psychopharmacology 1987; 93: 336-342.
118. Zhang M, Ouagazzal A, Creese I. Differential roles for dopamine 'D2' receptor subtypes in locomotor activity and stereotypy: antisense knockout studies. Soc. Neurosci. Abstr. 1995; 21: 364.
119. Sun B-C, Creese I, Tepper JM. Electrophysiology of antisense knockout of D2 and D3 dopamine receptors in nigrostriatal neurons. Soc. Neurosci. Abstr. 1995; 21: 1661.
120. Nissbrandt H, Ekman A, Eriksson E, Heilig M. Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. NeuroReport 1995; 6: 573-576.
121. Zhang SP, Zhou LW, Weiss B. Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 1994; 271: 1462-1470.
122. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
123. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
124. Lu D, Raizada MK. Delivery of angiotensin II type 1 receptor antisense inhibits angiotensin action in neurons from hypertensive rat brain. Proc. Natl. Acad. Sci. USA 1995; 92: 2914-2918.